糖尿病黄斑水肿治疗期间屈光不正的变化:糖尿病视网膜病变临床研究方案T的事后分析
该研究为糖尿病视网膜病变临床研究方案T的事后分析,纳入543只研究眼,评估抗血管内皮生长因子治疗对糖尿病黄斑水肿眼屈光不正的影响。结果显示研究眼2年等效球镜呈远视漂移0.04(0.82)D(P=0.022),对侧眼远视漂移0.12(0.84)D(P=0.001);有水肿眼与水肿消退眼间等效球镜变化无显著差异,且等效球镜变化与中央亚区厚度变化不相关(r=0.02,P=0.62)。结论认为糖尿病黄斑水肿患者屈光不正变化极小,治疗期间可考虑矫正屈光不正,无论是否存在水肿。
要点
- 研究眼2年等效球镜呈远视漂移0.04(0.82)D(P=0.022),对侧眼远视漂移0.12(0.84)D(P=0.001)。
- 有水肿眼与水肿消退眼2年等效球镜变化无显著差异:有晶状体眼0.12D与0.08D(P=0.87),人工晶状体眼-0.24D与-0.08D(P=0.30)。
- 等效球镜变化与第2年末中央亚区厚度变化不相关(r=0.02,P=0.62)。
核心结论
- 糖尿病黄斑水肿患者屈光不正变化极小,治疗期间可考虑矫正屈光不正,无论是否存在水肿。
研究设计与样本
- 糖尿病视网膜病变临床研究方案T的事后分析,共543只研究眼,在基线、1年和2年访视时计算研究眼与对侧眼的等效球镜。
主要发现
- 研究眼等效球镜从基线-0.17(2.04)D变为2年时-0.16(2.14)D,远视漂移0.04(0.82)D(P=0.022)。
- 对侧眼平均(标准差)等效球镜从基线-0.19(2.1)D变为2年时-0.11(2.1)D,远视漂移0.12(0.84)D(P=0.001)。
- 2年时有水肿眼与无水肿眼等效球镜变化无显著差异:有晶状体眼0.12D与0.08D(P=0.87),人工晶状体眼-0.24D与-0.08D(P=0.30)。
- 等效球镜变化与第2年末中央亚区厚度变化不相关(r=0.02,P=0.62)。
临床怎么用
- 作者认为,糖尿病黄斑水肿患者屈光不正变化极小,治疗期间可考虑矫正屈光不正,无论是否存在水肿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of anti-vascular endothelial growth factor therapy on the refractive error in eyes with diabetic macular edema. METHODS: Post hoc analysis of Diabetic Retinopathy Clinical Research protocol T. Spherical equivalent (SE) was calculated for study and fellow eyes at baseline, 1-year, and 2-year visits. The SE change of the eyes with edema was compared with those with resolved edema. The correlation between refractive error changes and central subfield thickness was evaluated. RESULTS: Among 543 study eyes, SE changed from -0.17 (2.04) D at baseline visit to -0.16 (2.14) D at 2 years giving a hyperopic shift of 0.04 (0.82) D (P = 0.022). Among fellow eyes, mean (SD) SE changed from -0.19 (2.1) D at baseline to -0.11 (2.1) D at 2 years, giving a hyperopic shift of 0.12 (0.84) D (P = 0.001). No significant difference in SE shift was found between eyes with and without edema at 2 years in phakic (0.12D and 0.08 D, P = 0.87) and pseudophakic eyes (-0.24D and -0.08D, P = 0.30). The SE shift was not correlated with central subfield thickness change at the end of the second year (r = 0.02, P = 0.62). CONCLUSION: Diabetic macular edema patients have minimal changes in refractive error. The correction of refractive error may be considered during treatment, regardless of the presence of edema.
引用
- Salabati M, Mahmoudzadeh R, Starr MR, et al. REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA: A Post Hoc Analysis of the Diabetic Retinopathy Clinical Research Protocol T Trial. Retina. 2022. PMID: 36269800. doi:10.1097/IAE.0000000000003583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。